{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:30:15Z","timestamp":1792639815524,"version":"4.5.0"},"reference-count":110,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T00:00:00Z","timestamp":1497312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>T\u2010cell lymphomas make up approximately 10%\u201015% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Diagnosis<\/jats:title><jats:p>The diagnosis of aggressive peripheral T\u2010cell lymphoma (PTCL) is usually made using the World Health Organization classification. The ability of hematopathologists to reproducibly diagnose aggressive PTCL is lower than that for aggressive B\u2010cell lymphomas, with a range of 72%\u201097% for the aggressive PTCLs. Risk Stratification: Patients with aggressive PTCL are staged using the Ann Arbor Classification. Although somewhat controversial, positron emission tomography scans seem to be useful as they are in aggressive B\u2010cell lymphomas. The specific subtype of aggressive PTCL is an important risk factor with the best survival seen in anaplastic large\u2010cell lymphoma\u2014particularly young patients with the anaplastic lymphoma kinase positive subtype.<\/jats:p><\/jats:sec><jats:sec><jats:title>Risk\u2010Adapted Therapy<\/jats:title><jats:p>Anaplastic large\u2010cell lymphoma is the only subgroup to have a good response to a CHOP\u2010like regimen. Angioimmunoblastic T\u2010cell lymphoma has a prolonged disease\u2010free survival in only \u223c20% of patients, but younger patients who have an autotransplant in remission seem to do better. PTCL\u2010not otherwise specified is not one disease. Anthracycline\u2010containing regimens have disappointing results, and a new approach is needed. Natural killer\/T\u2010cell lymphoma localized to the nose and nasal sinuses seems to be best treated with radiotherapy\u2010containing regimens and the majority of patients are cured. Enteropathy\u2010associated PTCL and hepatosplenic PTCL are rare disorders with a generally poor response to therapy although selected patients with enteropathy\u2010 associated PTCL seem to benefit from intensive therapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ajh.24791","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T05:36:44Z","timestamp":1495085804000},"page":"706-715","source":"Crossref","is-referenced-by-count":93,"title":["The aggressive peripheral T\u2010cell lymphomas: 2017"],"prefix":"10.1002","volume":"92","author":[{"given":"James O.","family":"Armitage","sequence":"first","affiliation":[{"name":"The Joe Shapiro Professor of Medicine, University of Nebraska Medical Center, 986840 Nebraska Medical Center, Omaha NE 68198"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"The Non\u2010Hodgkin's Lymphoma Classification Project","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group classification of non Hodg\u2010 kin's lymphoma","year":"1997","journal-title":"Blood."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265532487"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197410)34:8 <1488::AID-CNCR2820340822>3.0.CO;2-C"},{"issue":"2","key":"e_1_2_6_7_1","first-page":"29","article-title":"Cytological and functional criteria for the classification of malignant lymphomata","volume":"31","author":"Lennert K","year":"1975","journal-title":"Br J Cancer Suppl."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_6_9_1","volume-title":"World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe E","year":"2001"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.320"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65454-5"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64441-0"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200103000-00002"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-227579"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-055145"},{"key":"e_1_2_6_17_1","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0494-8"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm265"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701344915"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08335.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq415"},{"issue":"4","key":"e_1_2_6_23_1","article-title":"FDG\u2010 PET in the staging and prognosis of T\u2010cell lym\u2010 phoma [Abstract]","volume":"22","author":"Casulo C","year":"2011","journal-title":"Ann Oncol."},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0463"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3080"},{"key":"e_1_2_6_26_1","author":"Went P","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3080"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571091"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.585"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0238"},{"key":"e_1_2_6_32_1","first-page":"e115","article-title":"Anaplastic large cell lymphoma arising in a silicone breast implant capsule: a case report and review of the literature","author":"Sahoo S","year":"2004","journal-title":"Arch Pathol Lab Med."},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)90553-4"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-692541"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-105759"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-692566"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-381921"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4197"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp418"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)91754-3"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(03)00302-4"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-335216"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65736-7"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.036"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.021"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcpc0800380"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21062"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"e_1_2_6_49_1","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood.V90.9.3727","article-title":"Primary anaplastic large\u2010cell lymphoma in adults: Clini\u2010 cal presentation, immunophenotype, and out\u2010 come","volume":"90","author":"Tilly H","year":"1997","journal-title":"Blood."},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1764"},{"key":"e_1_2_6_51_1","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2010.28.5999","article-title":"Vinblastine in children and adolescents with high\u2010risk anaplastic large\u2010cell lymphoma: Results of the randomized ALCL99\u2010vinblastine trial","volume":"28","author":"Le Deley MC","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_52_1","article-title":"Brentuximab Vedotin (SGN\u201035) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: A phase 2 study update [Abstract]","volume":"117","author":"Advani R","year":"2011","journal-title":"Blood."},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0034"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1013224"},{"key":"e_1_2_6_55_1","first-page":"472","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large\u2010cell lymphoma: A children's Oncology Group phase 1 consortium study","author":"Mosse YP","journal-title":"Lancet Oncol."},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1524-0"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr140"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.3412"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv575"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.02.008"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14477"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-692541"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-5-364"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08003.x"},{"key":"e_1_2_6_66_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2686.2686","article-title":"Rituximab in combination with CHOP regimen in angioimmunoblastic T\u2010cell lymphomas (AITL): Pre\u2010 liminary results in 9 patients treated in a single insti\u2010 tution [Abstract]","volume":"106","author":"Joly B","year":"2005","journal-title":"Blood."},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.8049"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190601137658"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403936"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm579"},{"issue":"4","key":"e_1_2_6_71_1","article-title":"Response to lenalidomide in heavily pre\u2010treated angioimmunoblastic T\u2010cell\u2010lymphoma (AITL) [Abstract]","volume":"22","author":"Rentschler J","year":"2011","journal-title":"Ann Oncol."},{"issue":"4","key":"e_1_2_6_72_1","article-title":"Long term disease control and overall survival after early dose intensification in T\u2010NHL depend on specific entities [Abstract]","volume":"22","author":"Marks R","year":"2011","journal-title":"Ann Oncol."},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.12.6219"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4628"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-692566"},{"key":"e_1_2_6_76_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4434.4434","article-title":"Patient characteristics and initial treatment patterns in the United States for the most common subtypes of peripheral T\u2010cell lymphoma (PTCL)","volume":"124","author":"Pinter\u2010Brown L","year":"2014","journal-title":"Blood."},{"key":"e_1_2_6_77_1","unstructured":"NCCN. NCCN Clinical Practice Guidelines in Oncology for Non\u2010Hodgkin's Lymphomas (TCEL\u20101) Version 4.2011.2011. Available at:www.NCCN.org"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"e_1_2_6_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074641"},{"key":"e_1_2_6_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.8045"},{"key":"e_1_2_6_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20999"},{"key":"e_1_2_6_82_1","first-page":"76","article-title":"Prognostic significance of T\u2010cell phenotype in aggressive non\u2010Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht C","year":"1998","journal-title":"Blood."},{"issue":"21","key":"e_1_2_6_83_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2829.2829","article-title":"Gemcitabine, ifosfamide, oxaliplatin (GIFOX) as first\u2010line treatment in high\u2010risk peripheral T\u2010 cell\/NK lymphomas: A phase II trial [Abstract]","volume":"116","author":"Corazzelli G","year":"2010","journal-title":"Blood."},{"issue":"2","key":"e_1_2_6_84_1","article-title":"Dose\u2010dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T\u2010cell lympho\u2010 mas (PTCLs)\u2013Overall and subtype\u2010specific results of a phase II study from Nordic lym\u2010 phoma group [Abstract]","volume":"94","author":"d'Amore F","year":"2009","journal-title":"Haematologica."},{"key":"e_1_2_6_85_1","first-page":"644","article-title":"Retrospective Analysis of Peripheral T\u2010Cell Lymphoma Treated With the Intention to Transplant in the First Remission","volume":"13","author":"Mehta N","year":"2013","journal-title":"Clin Lymphoma Myleoma Leuk."},{"key":"e_1_2_6_86_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_6_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603"},{"key":"e_1_2_6_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25377"},{"key":"e_1_2_6_89_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.288.288","article-title":"Phase I\/II study of dasatinib in relapsed or refractory non\u2010Hodgkin's lymphoma (NHL) [Abstract]","volume":"116","author":"William BM","year":"2010","journal-title":"Blood."},{"key":"e_1_2_6_90_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.95.95","article-title":"Phase 2 Trial of Alisertib (MLN8237), an investigational, potent inhibitor of auror a kinase (AAK), in patients (pts) with aggressive B\u2010 and T\u2010cell non\u2010Hodgkin lymphoma (NHL) [Abstract]","volume":"118","author":"Friedberg J","year":"2011","journal-title":"Blood."},{"key":"e_1_2_6_91_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5094"},{"key":"e_1_2_6_92_1","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1182\/blood.V89.8.2966","article-title":"CD3 CD561 non\u2010Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance","volume":"89","author":"Drenou B","year":"1997","journal-title":"Blood."},{"key":"e_1_2_6_93_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009053547"},{"key":"e_1_2_6_94_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982090"},{"key":"e_1_2_6_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-453233"},{"key":"e_1_2_6_96_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.1619"},{"key":"e_1_2_6_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.795"},{"key":"e_1_2_6_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-231324"},{"key":"e_1_2_6_99_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0021"},{"key":"e_1_2_6_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1675"},{"key":"e_1_2_6_101_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn119"},{"key":"e_1_2_6_102_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109099342"},{"key":"e_1_2_6_103_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705615"},{"key":"e_1_2_6_104_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn751"},{"key":"e_1_2_6_105_1","doi-asserted-by":"crossref","unstructured":"VossMH LunningMA MaraguliaJC et al. Intensive induction chemotherapy followed by early high\u2010dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T\u2010cell lymphoma: a single institution experience.Clin Lymphoma Myeloma Leuk.2013;13:8\u201314.","DOI":"10.1016\/j.clml.2012.09.002"},{"key":"e_1_2_6_106_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_6_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)90004-1"},{"key":"e_1_2_6_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.11.4265.bloodjournal88114265"},{"issue":"21","key":"e_1_2_6_109_1","article-title":"The efficacy of bortezomib CHOP in patients with advanced stage T or NK\/T cell lymphomas: The results of multicenter phase II study [Abstract]","volume":"116","author":"Kim SJ","year":"2010","journal-title":"Blood."},{"key":"e_1_2_6_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"e_1_2_6_111_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6287"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:32:02Z","timestamp":1695573122000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,13]]},"references-count":110,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1002\/ajh.24791"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24791","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,13]]}}}